Compare AOUT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOUT | ALXO |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.9M | 205.9M |
| IPO Year | 2020 | 2020 |
| Metric | AOUT | ALXO |
|---|---|---|
| Price | $12.95 | $2.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $12.50 | $3.50 |
| AVG Volume (30 Days) | 198.0K | ★ 1.6M |
| Earning Date | 03-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,536,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.26 | $0.51 |
| 52 Week High | $14.97 | $2.66 |
| Indicator | AOUT | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 53.04 |
| Support Level | $8.04 | $1.96 |
| Resistance Level | $14.97 | $2.31 |
| Average True Range (ATR) | 0.72 | 0.17 |
| MACD | -0.24 | -0.02 |
| Stochastic Oscillator | 19.12 | 28.43 |
American Outdoor Brands Inc is the provider of outdoor lifestyle products and shooting sports accessories encompassing hunting, fishing, meat processing, outdoor cooking, shooting, and personal security and defense products for rugged outdoor enthusiasts. It conceive, design, produce or source, and sell its outdoor lifestyle products including premium sportsman knives, land management tools, products used while hunting, meat processing equipment; and outdoor cooking products and hooting sports accessories, including rests, vaults, and other related accessories, electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips, etc. The company operate as one reporting segment.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.